---
schema_version: "secwatch.filing_event.v1"
accession: "0001651944-24-000005"
form_type: "8-K"
ticker: null
cik: "0001651944"
company_name: "DermTech, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:43:36.038978+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DermTech cuts 15% of workforce (~30 employees); COO departs; targets $40M savings

## Summary
- Workforce reduction of ~30 employees (~15% of total) approved by Board on Jan 29, 2024.
- Combined with June 2023 plan, expects ~$40M total operating expense reductions vs FY2022.
- One-time pre-tax charge of ~$1.3M in Q1 2024 for severance and related costs.
- COO Claudia Ibarra's last day is Feb 2, 2024; separation agreement terms pending.
- Company focuses resources on growing reimbursed DMT billable samples and payer coverage.

## SEC filing metadata
- accession: 0001651944-24-000005
- form_type: 8-K
- cik: 0001651944
- company_name: DermTech, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000005/0001651944-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000005/dmtk-20240129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651944-24-000005
- JSON: https://secwatch.observer/filing/0001651944-24-000005.json
- Plain text: https://secwatch.observer/filing/0001651944-24-000005.txt

## Key facts
- Executive change
  Claudia Ibarra departed as chief operating officer at DermTech, Inc..
  - Action: mutually agreed departure
  - Role: chief operating officer
  source text: On January 29, 2024, Claudia Ibarra and the Company mutually agreed Ms. Ibarra’s last day of employment as chief operating officer of the Company will be February 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000005/0001651944-24-000005-index.htm
- Restructurings & Charges
  DermTech, Inc. announced a restructuring with charges of approximately $1.3 million affecting operations (approximately 30 employees, or approximately 15% of the Company's workforce).
  - Type: restructuring
  - Charge: approximately $1.3 million
  - Affected area: operations
  - Headcount: approximately 30 employees, or approximately 15% of the Company's workforce
  source text: On January 29, 2024, the Board of Directors (the “Board”) of DermTech, Inc. (the “Company”) approved a restructuring plan to continue to align the Company’s resources with its previously announced strategic prioritization for the DermTech Melanoma Test, further streamline operations and reduce overall operating expenses. The restructuring includes operating expense reductions and a reduction in force (the “Reduction in Force”). These additional restructuring actions will primarily affect operations, but impact the entire organization, and will result in a workforce reduction of approximately 30 employees, or approximately 15% of the Company's workforce. The Company expects to achieve approximately $40 million in total operating expense reductions compared to fiscal 2022, when combined with its initial restructuring plan announced in June 2023. The Company estimates that it will incur aggregate pre-tax charges of approximately $1.3 million in connection with the Reduction in Force, prim
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000005/0001651944-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.